Zhongke Aug completed over 200 million yuan in Series A3 financing.

On August 7, according to Lenovo Capital news, Chengdu Zhongke Auge Biotechnology Co., Ltd., a company in the field of xenotransplantation in China, announced the completion of over 200 million yuan in A3 round financing in August 2026. This round of financing was led by Zhongke Chuangxing, with participation from Lenovo Capital, Muyuan Group, Weigao Blood Purification, Huali Group, Huafang Capital, and Chengdu Science and Technology Investment, while existing shareholders Beida Fund and Guanghe Venture Capital continued to increase their investments. Kaicheng Capital acted as the exclusive financial advisor for this round. The funds will mainly be used for the application and promotion of clinical trials for xenotransplantation products, the expansion of production capacity for DPF-grade medical donor pigs, the construction of industrial bases, and the development of a new generation of multi-gene edited donor pigs.